Perspectives on stimulating industrial research and development for neglected infectious diseases

Bulletin of the World Health Organization

Volumn 79, Issue 8, 2001, Pages 735-741

  Webber, David ^a   Kremer, Michael ^b,c  

^a International Federation of Pharmaceutical Manufacturers and Associations   (Switzerland)

^b HARVARD UNIVERSITY   (United States)

^c BROOKINGS INSTITUTION   (United States)

Author keywords

Communicable diseases drug therapy; Cost benefit analysis; Drug industry; Drugs, Investigational supply and distribution; Financial support; Motivation; Orphan drug production; Patents (source: MeSH); Private sector; Research economics

Indexed keywords

DISEASE CONTROL; DRUG DEVELOPMENT; HEALTH SERVICES; INFECTIOUS DISEASE; RESEARCH AND DEVELOPMENT;

ARTICLE; COMMUNICABLE DISEASE; COST BENEFIT ANALYSIS; DRUG RESEARCH; HEALTH CARE FINANCING; HEALTH PROGRAM; INFECTION CONTROL; INVESTMENT; MARKETING;

COMMUNICABLE DISEASES; COST-BENEFIT ANALYSIS; DRUG INDUSTRY; HUMANS; INVESTMENTS; PATENTS; PRIVATE SECTOR; RESEARCH; RESEARCH SUPPORT; TAX EXEMPTION; WORLD HEALTH;

EID: 0034890738     PISSN: 00429686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Global patterns of cause of death and burden of disease in 1990, with projections to 2020
2. Access to essential drugs in poor countries. A lost battle?
3. Cost of innovation in the pharmaceutical industry
4. Cure for indifference
5. International action against child poverty - Meeting the 2015 targets